Robert Pace, MD
Neurology · Owosso, MINPI 1144483660
Payments from drug & device makers
Across 1,102 payments — averaging $913.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$304K
- EMD Serono, Inc.$266K
- Biogen$129K
- Novartis$105K
- Genentech USA, Inc.$89K
- TG Therapeutics, Inc.$57K
- plus $57K from 30 others
Across 9 payments — averaging $592.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$5K
- AbbVie$546
- EMD Serono, Inc.$261
What the payments were for
- Consulting fees$89,40913%
- Speaking & faculty fees$534,04277%
- Travel & lodging$49,1897%
- Food & beverage$20,1003%
- Education$2690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 225 | $304,377 |
| EMD Serono, Inc. | 266 | $265,517 |
| Biogen | 157 | $128,834 |
| Novartis | 134 | $105,356 |
| Genentech USA, Inc. | 73 | $88,605 |
| TG Therapeutics, Inc. | 67 | $57,138 |
| E.r. Squibb & Sons, L.L.C. | 16 | $22,396 |
| Bristol Myers Squibb | 51 | $17,935 |
| Genentech, Inc. | 9 | $14,399 |
| AbbVie(2 entities) | 36 | $499 |
| Amgen(2 entities) | 6 | $134 |
| AstraZeneca | 5 | $118 |
| Lilly USA, LLC | 7 | $97 |
| Teva Pharmaceuticals USA, Inc. | 6 | $88 |
| Johnson & Johnson | 5 | $85 |
| UCB, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 2 | $70 |
| Avanir Pharmaceuticals, Inc. | 3 | $65 |
| Lundbeck LLC | 3 | $64 |
| Pfizer | 3 | $61 |
| Vanda Pharmaceuticals Inc. | 2 | $55 |
| Merz Pharmaceuticals, LLC | 2 | $55 |
| CSL Behring | 3 | $47 |
| Grifols USA, LLC | 2 | $45 |
| Eisai Inc. | 2 | $43 |
| Acorda Therapeutics, Inc | 2 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Corium, LLC | 1 | $14 |
| Resmed Corp | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,006,421 in reported general payments places this provider in the 95th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 284 | $2,503,084 |
| MayzentSiponimod | 31 | $287,914 |
| Dalfampridine ErDalfampridine | 322 | $127,616 |
| AubagioTeriflunomide | 14 | $121,598 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $100,569 |
| IngrezzaValbenazine Tosylate | 12 | $97,179 |
| AmpyraDalfampridine | 15 | $96,309 |
| TysabriNatalizumab | 11 | $86,166 |
| CopaxoneGlatiramer Acetate | 15 | $86,076 |
| Teriflunomide | 70 | $85,005 |
| NuedextaDextromethorphan Hbr/Quinidine | 36 | $45,547 |
| FingolimodFingolimod Hcl | 24 | $37,743 |
| Aimovig AutoinjectorErenumab-Aooe | 46 | $33,078 |
| MyrbetriqMirabegron | 47 | $31,382 |
| Oxtellar XrOxcarbazepine | 12 | $29,844 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent | $105,356 | $287,91431 claims |
| SanofiAubagio | $304,377 | $121,59814 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $16 | $97,17912 claims |
| Acorda Therapeutics, IncAmpyra | $42 | $96,30915 claims |
| BiogenTysabri | $128,834 | $86,16611 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $88 | $86,07615 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $65 | $45,54736 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $18 | $29,84412 claims |
| AbbVieUbrelvy | $499 | $17,26613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 652 neurology providers in Michigan.
Other neurology in Owosso
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
- Rosemarie WalchOwosso$757K
- Margaret FreyOwosso$540K
- Cara LeahyOwosso$214K
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.